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Abstract 
Myelodysplastic syndromes (MDS) tradition-
ally have been grouped together as a disease
entity  based  on  clinical  phenomena  seen  in
association. Despite the similarities, there is
great  heterogeneity  among  the  syndromes.
Recent  insights  have  shown,  however,  that
there exists a biologically cohesive theme that
unifies  and  thereby  validates  the  conceptual
interconnectedness. The first suggestion that
such a relationship existed where biology could
directly explain the observed cytopenias was the
finding  of  excessive  premature  apoptosis  of
hematopoietic  cells  in  MDS  marrows.  This
apoptosis was mediated by paracrine as well as
autocrine factors implicating both the seed and
the soil in the pathology of the disease. Pro-
inflammatory cytokines in the marrow microen-
vironment were mainly the paracrine mediators
of apoptosis, but how the clonal cells committed
suicide because of autocrine stimulation had
remained a mystery for more than a decade. It
has been shown now that deregulation of ribo-
some biogenesis can initiate a stress response
in the cell through the p53 signaling pathway.
Congenital anemias had been associated with
mutations in ribosomal protein genes. The sur-
prise came with the investigation of 5q- syn-
drome patients where haplo-insufficiency of the
ribosomal protein gene RPS14 was found to be
the cause of this MDS subtype. Similar riboso-
mal deregulation was shown to be present in all
varieties of MDS patients, serving as another
unifying  characteristic.  In  addition  to  these
findings, there are other DNA-related abnormal-
ities such as uniparental disomy, mutations in
the TET2 gene, and epigenetic phenomena that
are associated with and occur across all types of
MDS. This paper summarizes the themes unify-
ing this heterogeneous group of diseases. 
Introduction 
While  an  improved  understanding  of  the
biology  helps  us  comprehend  disease
manifest  ations better, the converse is also true
in  that  clinical  observations  can  sometimes
provide critical clues into the underlying biology
of the disease. MDS exemplify this. These syn-
dromes, which predominate in the elderly, are
characterized  by  the  presence  of  a  variable
cytopenia, with a third of the cases progressing
to acute myeloid leukemia (AML). The initial,
as yet poorly understood lesion strikes an early
hematopoietic stem cell that develops a growth
advantage over its normal neighbors and leads
to clonal expansion and eventual monoclonal
hematopoiesis. Detailed studies of cell cycle
kinetics  revealed  that  the  marrow  is  quite
actively  proliferative  with  more  cells  in  S-
phase  and  cycling  faster  than  even  normal
marrows. The presence of cytopenias in the
background  of  such  active  proliferation  was
difficult  to  explain  initially.  This  paper
summar  izes the mechanism of the underlying
cytopenias  in  MDS,  which  turned  out  to  be
caused by a premature intramedullary apoptot-
ic  death  of  hematopoietic  cells.  Apoptosis,
therefore, was the first biologic characteristic
to be found in different sub-categories of MDS
patients, albeit in varying degrees, thus unify-
ing the disparate group of diseases through
biology for the first time. Since then, several
additional  unifying  biologic  features  have
been described and are discussed here.
Excessive apoptosis in the
myelodysplastic syndromes cell
or the seed 
It was recognized early through a number of
sophisticated  studies  performed  in  female
African-American patients heterogeneous for
the enzyme G6PD that MDS is a clonal disease.
Cell cycle studies using in vivoinfusions of the
thymidine analogues bromodeoxyuridine and
iododeoxyuridine  further  demonstrated  the
highly expanded nature of the clone to be the
result of excessive proliferation of hematopoi-
etic progenitors in the marrow.1-3 How such an
expanded  clone  could  produce  peripheral
cytopenias remained a mystery for some time.
It was only in the 1990s when the phenomenon
of programmed cell death through the peculiar
mode  of  apoptotic  cellular  suicide  had  been
described that the paradox of cytopenia in the
presence of a cellular marrow of MDS patients
was resolved finally. It appeared that the exces-
sive  proliferation  in  the  marrows  of  MDS
patients was matched by an equally excessive
intramedullary  apoptosis  of  hematopoietic
cells.4-6 This apoptosis was seen in all FAB cat-
egories of patients, although it was higher in
those with lower risk disease and proportion-
ately  lower  in  patients  with  increasing  per-
centage of blasts. Furthermore, it was shown
that  the  excessive  apoptosis  was  largely
cytokine  mediated  with  a  number  of  pro-
inflammatory cytokines being over-expressed
in  the  marrows  of  these  patients;  such  as
tumor  necrosis  factor  alpha  (TNFa),  trans-
forming growth factor beta (TGFb), and inter-
leukin  1  beta  (IL1b).6-9 A  second  important
para  dox at this point was the presence of clon-
al expansion and monoclonality in cells that
appeared to be prone to premature apoptotic
death. A model was proposed to explain this
second paradox in which an unknown, poorly
understood,  initial  lesion  in  a  pluripotential
hematopoietic stem cell leads to this cell devel-
oping a growth advantage.6 The cells are stim-
ulated further to proliferate through the effects
of pro-inflammatory cytokine TNFa. This even-
tually  leads  to  a  monoclonal  hematopoiesis.
Interestingly, as the daughter cells mature, the
very cytokines driving the proliferation of the
progenitors  can  exert  a  dual  action  in  that
apoptosis is induced in the maturing progeny.
The  propensity  to  undergo  apoptosis  is  not
inherited uniformly by all the daughter cells;
rather there is a spectrum of sensitivity to the
pro-inflammatory  cytokines.  The  cells  most
sensitive to apoptosis are the ones undergoing
premature death in the marrow while those
most resistant to it are the cells that actually
make it out to the blood. This has been sup-
ported by showing that granulocytes in MDS
patients, although clonal in nature, are more
resistant  to  apoptosis  than  granulocytes
obtained from normal, healthy donors.10
To  summarize,  it  seems  that  an  early
hematopoietic  progenitor  develops  a  growth
advantage for a poorly understood reason and
clonal expansion results, eventually leading to
monoclonality. Daughters of this transformed
clone have an unequal tendency for premature
apoptotic death in the presence of increased
amounts  of  a  cascade  of  pro-inflammatory
cytokines whose master switch appears to be
TNFa. Thus the clinical manifestations of the
disease arise from the contributions of both the
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cell  (seed)  and  its  microenvironment  (soil).
MDS must be viewed, therefore, as a disease of
the seed and soil, a concept which is now gain-
ing credence in other malignancies as well and
which becomes critical when designing thera-
peutic approaches, especially those directed at
changing  the  natural  history  of  the  disease.
Apoptosis,  therefore,  was  the  first  biologic
characteristic present in all subtypes of MDS. 
Abnormal soil or a pro-inflam-
matory bone marrow micro  -
environment 
While a molecular or genetic lesion can con-
vert a hematopoetic cell into an MDS seed, it
cannot thrive in vivo unless it is received by a
complementary soil that is especially prepared
to  nourish  it.  There  is  ample  evidence  from
many sources that the bone marrow microenvi-
ronment  in  MDS  mimics  a  pro-inflammatory
milieu with increased angiogenesis, infiltration
by immune regulatory cells, and most impor-
tantly, an abundance of pro-apoptotic cytokines
such as TNFa, IL1b, TGFb, etc.6-9 Once again,
these changes have been described with vary-
ing  intensities  in  all  different  types  of  MDS
patients, be they low or high risk, and constitute
a second unifying theme for these disorders. 
Defective biogenesis
A third unifying theme that has been discov-
ered in the last few years relates to defective
ribosomal  biogenesis.  This  interesting  story
started  with  a  study  of  the  most  common
chromo  somal  abnormality  in  MDS  patients
that affects chromosome 5 with two regions of
deletions in the long arm. Patients with 5q-
syndrome have been recognized as a distinct
clinical entity for 35 years. These individuals
present  with  the  more  telomeric  of  the  two
deleted regions on 5q, anemia, normal or high
platelet counts, no increase in blasts, a marrow
filled  with  clusters  of  hypolobated  micro-
megakaryocytes, rarely transform to AML, and
have long survival. While the deletion on 5q
can  be  variable  in  length,  a  1.5MB  region
flanked  by  marker  D5S413  and  the  gene
GLRA1,  and  containing  40  genes,  called  the
Commonly Deleted Region (CDR), is missing
universally in these patients.11 Not surprising-
ly, a search for candidate genes that could be
the cause of 5q- syndrome has focused on the
CDR. Two ribosomal genes, RBM22 and RPS14,
are located within the CDR but while no muta-
tion in the normal allele was found, Boultwood
et al. noted that their expression was reduced
(haplo-insufficiency).11,12 Ebert  et  al.  used
RNAi to silence one gene at a time in the CDR
in  normal  bone  marrow  CD34+ cells,13 and
showed that it was the knock-down of a single
gene, RPS14, which resulted in the apoptosis
of erythroid cells while preserving megakaryo  -
poiesis.  Equally  impressive  was  the  finding
that when the expression of RPS14 was forced
in the diseased cells of 5q- syndrome patients,
it rescued the phenotype. RPS14 is a universal
structural protein of the 40S ribosomal subunit
that is essential for the cleavage of the 30S
precursor  rRNA  molecule  into  the  18SE/18S
rRNA molecule. Haplo-insufficiency of RPS14
in MDS with del(5q) leads to impaired process-
ing of the 18S ribosomal RNA with subsequent
disruption  of  the  small  40S  subunit.
Furthermore,  haplo-insufficiency  of  RPS14
also explains the paradox of anemia and high
number  of  platelets  in  that  rapidly  dividing
cells  such  as  erythroid  precursors  apoptose
with the slightest disruption in ribosomal bio-
genesis, causing anemia, while slowly prolifer-
ating ones like megakaryocytes could accumu-
late the 50% reduced dose and continue prolif-
eration (high number of platelets). One caveat
in  this  defective  ribogenesis  story  is  that  it
does not explain the initial clonal expansion,
only the apoptosis in the progeny of the MDS
stem cell. 
More recently, expression of multiple genes
associated with ribosome biogenesis was found
to be decreased in CD34+ cells from del(5q)
patients when compared to that from refractory
anemia (RA) patients with normal karyotypes,
as well as with healthy controls.14 Another study
shows that a proportion of non-del(5q) patients
have low RPS14 expression when compared to
normal controls and that these levels are simi-
lar  to  that  of  5q-  syndrome  MDS  patients.15
These findings clearly indicate that defective
ribogenesis is not limited to the 5q- syndrome
MDS patients but is a more widespread finding
across the various subtypes and therefore con-
stitutes  another  theme  that  links  the  syn-
dromes of MDS through biology. The generality
of defective ribogenesis described here is sup-
ported  by  the  finding  of  congenital  anemias
such as dyskeratosis congenita, cartilage-hair
hypoplasia,  Diamond-Blackfan  anemia,  and
Shwachman-Diamond syndrome.16-20
The molecular basis of excessive
apoptosis in myelodysplastic
syndromes: role of p53
The most prominent clinical characteristic
of  MDS,  a  variable  cytopenia,  has  been
explained  by  a  propensity  of  the  maturing
hematopoietic  cells  in  the  bone  marrow  to
undergo premature apoptosis. While apoptosis
is  at  least  partially  mediated  through  pro-
inflammatory cytokines found in the microen-
vironment,  the  clonal  cells  themselves  also
manifest the tendency to apoptose outside of
the  abnormal  soil.  Thus  both  paracrine  and
autocrine factors contribute to the excessive
apoptosis in MDS. While the cytokines repre-
sent  the  paracrine  influence,  an  interesting
new  genetic  candidate  has  emerged  as  the
autocrine mediator of apoptosis, as a result of
the defective ribogenesis story. The tumor sup-
pressor gene p53is well recognized as exerting
nodal control over multiple pathways including
apoptosis. The ribosome stress response refers
to the increased expression of p53 as a direct
result of defective ribogenesis.21-23Barlow et al.
found  that  elevated  levels  of  p53 drive  the
excessive apoptosis and dysplastic morphology
in the erythroid compartment of mice lacking
the RPS14 gene through deletion of 5q.24 The
cytopenias in MDS thus may be the result of
deregulated ribosomal biosynthesis leading to
activation of p53 and excessive apoptosis. 
Mutations in TET2 in myeloid
diseases
It was hypothesized that the earliest lesion
that leads to the initial clonal expansion may
be  common  across  several  myeloid  diseases
including  MDS,  myeloproliferative  disorders
(MPD), and AML. It was found that somatic
mutations in the TET2 gene were present in
15% of patients with various myeloid cancers
(19%  in  MDS,  12%  in  MPD,  and  24%  in
AML).25,26 This gene is present on chromosome
4q and its precise function is unknown; how  -
ever, wild-type TET2 appears to control the bal-
ance between survival, apoptosis, and differen-
tiation  in  normal  hematopoiesis.  In  a  study
published  in  2009,  mutations  or  defects  in
gene structure were identified in 23% of MDS
patients.27 While patients with mutated TET2
did not differ significantly in clinical or hema-
tological presentation from patients with wild-
type TET2, the five-year overall survival was
77%  in  mutated  versus  18%  in  un-mutated
patients, indicating that TET2 mutations are
associated with a good prognosis. A lower rate
of transformation to AML in mutated patients
might account for this survival advantage. In a
multivariate analysis, TET2 mutation emerged
as  an  independent  good  prognostic  factor
while the absence of TET2 mutation was asso-
ciated with a five-fold increase in the risk of
death.27 Prospective  studies  might  establish
the  value  of  TET2 mutational  status  as  an
important parameter for prognostic stratifica-
tion in MDS. Thus TET2 mutation unifies not
only the syndromes of myelodysplasia but also
several myeloid malignancies. 
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Uniparental disomy 
Small genetic lesions such as uniparental
disomy (UPD) could not be detected until high
density single nucleotide polymorphism (SNP)
arrays  were  developed.  When  MDS  patients
were studied, it was found that 10-15% of those
with apparently normal karyotypes had regions
of DNA that were derived from only one parent.
This phenomenon has been termed UPD.28-30In
addition, small genetic lesions such as amplifi-
cations  and  deletions,  which  had  remained
undetected by cytogenetics or FISH analyses,
were also discovered. While UPDs were consti-
tutional and not limited to the clonal cells, the
amplifications and deletions turned out to be
acquired. These data suggest that individuals
who are born with constitutional UPDs may be
predisposed toward genetic instability and an
increased  risk  for  developing  MDS.  Once
again, this biologic feature transcends the var-
ious subtypes of MDS and is found in patients
with both low and high risk disease. 
Epigenetics
Genetic  mutations  and  structural  changes
are not the only causes for a cell to become can-
cerous. The last few decades have demonstrat-
ed the extraordinary role played by epigenetics,
so that today it is believed that a mixture of
both  genetic  and  epigenetic  changes  partici-
pate  in  the  transformation  process.31,32 Thus
while epigenetic silencing of tumor suppressor
genes through hypermethylation is found in a
variety  of  cancers,  epigenetics  plays  a  more
prominent  role  in  MDS  where  only  10%  of
patients  actually  present  with  identifiable
genetic  lesions  and  ~50%  respond  to  hypo-
methylating drugs. MDS is known to be a dis-
ease of the elderly, and repetitive stem cell div  -
ision that occurs during aging leads to an accu-
mulation  of  epigenetic  damage  to  the  DNA,
making the cell susceptible to neoplastic trans-
formation. Unlike genetic damages, it is some-
times possible to reverse epigenetic changes,
be they hypermethylation or histone deacetyl  -
ation.  Two  hypomethylating  agents  are  FDA
approved for the treatment of MDS and provide
support for the contribution made by epigenet-
ics in the pathology of these disorders.32
Concluding remarks
Unity despite heterogeneity 
As the name itself implies, MDS is not a sin-
gle disease entity but consists of a collection of
syndromes  that  generally  have  been  divided
into those that are at high risk of transform -
ation  to  acute  leukemia  versus  those  that
prove fatal through an increasing profundity of
cytopenias.  Biologic  heterogeneity  naturally
parallels the clinical diversity. Over the years,
however, the principle underlying the need to
collect  these  syndromes  under  one  title  has
been vindicated as more and more biologic fea-
tures common to all types of MDS have been
identified. Apoptosis, the first link in this the-
matic  cohesion,  accounts  for  the  cytopenias
that underlie the clinical manifestations of the
syndromes. Paradoxically enough, this propen-
sity  to  undergo  a  premature  programmed
death is not a property of the MDS progenitor,
because if it were, there would be no clonal
expansion to begin with. Rather, most of the
apoptotic  signals  are  mediated  through  the
cytokines in the marrow microenvironment. It
has been shown that it is only when the daugh-
ters of this MDS progenitor cell mature and
begin  to  express  the  appropriate  cytokine
receptors  that  premature  apoptotic  death  is
induced  in  the  hematopoietic  cells.33 These
insights led to the novel translational approach
of using anti-cytokine therapy to improve the
cytopenias  by  protecting  the  maturing  cells
from dying. This strategy was attempted with-
out  a  serious  concern  for  causing  leukemic
transformation as the apoptosis did not affect
earlier progenitors. Because the rate of apop-
tosis  is  inversely  related  to  the  risk  of
transform  ation,  this  strategy  worked  best  in
patients with lower risk MDS where anti-TNF
agents like thalidomide, lenalidomide, inflix-
imab, and etanercept have been found to be
effective in improving the cytopenias in a sub-
set of patients. It is important to note that even
high risk patients have the same incidence of
apoptosis in the maturing cells as lower risk
patients; it is only the immature blasts that are
not dying, which accounts for the lower overall
incidence of apoptosis in this group. 
A totally unexpected area of research has
been inaugurated with the discovery of defect  -
ive  ribogenesis  in  both  congenital  and
acquired  anemias.  In  MDS,  it  was  RPS14
haplo-insufficiency  that  was  found  to  be
causative  for  the  5q-  syndrome.  This  was
quickly  followed  by  studies  identifying
abnorm  al  ribosomal  gene  expression  in  all
subtypes  of  MDS.  Defective  ribogenesis  has
been  known  to  cause  the  stress  response
inducing  apoptosis  via  p53 up-regulation.
Finally, we have a molecular explanation for
the autocrine-induced apoptosis in MDS clonal
cells.  Both  TET2 mutations  and  UPD  are
indicative  of  genetic  instability  whose  pres-
ence renders the affected cell prone to both
initiation as well as progression of MDS. 
One of the hottest areas of research in can-
cer  is  epigenetics,  which  clearly  affects  the
ability  of  a  cell  to  differentiate  and  die.  It
acquired  a  particular  significance  in  MDS
because of the effectiveness of hypomethylat-
ing drugs in improving the cytopenias in these
patients. Initially it was thought that silenced
methylated  tumor  suppressor  genes  were
being  reactivated  through  hypomethylation
resulting in apoptosis of clonal cells and regen-
eration  of  normal  hematopoietic  cells.
However, despite multiple attempts to identify
both specific genes targeted by the hypomethy-
lating drugs as well as global methylation pat-
terns,  it  has  not  been  possible  to  correlate
gene methylation status with therapeutic out-
come. Nonetheless, the observation that these
agents  are  effective  in  all  subtypes  of  MDS
once  again  underscores  the  biologic  unity
despite the clinical heterogeneity of MDS. 
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